Evidence map›Paper›PMID 39062067›Full record

ArticleBiomedicines2024

Evidence-Based Severity Assessment of Animal Models for Pancreatic Cancer.

Tim Schreiber, Ingo Koopmann, Jakob Brandstetter, Steven R Talbot, Lea Goldstein, Lisa Hoffmann, Anna Schildt, Markus Joksch, Bernd Krause, Robert Jaster and 4 more

Abstract read
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Tim SchreiberRudolf-Zenker-Institute of Experimental Surgery, Rostock University Medical Center, 18057 Rostock, Germany.
Ingo KoopmannRudolf-Zenker-Institute of Experimental Surgery, Rostock University Medical Center, 18057 Rostock, Germany.ORCID 0009-0006-0898-822X
Jakob BrandstetterRudolf-Zenker-Institute of Experimental Surgery, Rostock University Medical Center, 18057 Rostock, Germany.
Steven R TalbotInstitute for Laboratory Animal Science, Preclinical Data Science, Hannover Medical School, 30625 Hannover, Germany.ORCID 0000-0002-9062-4065
Lea GoldsteinRudolf-Zenker-Institute of Experimental Surgery, Rostock University Medical Center, 18057 Rostock, Germany.
Lisa HoffmannRudolf-Zenker-Institute of Experimental Surgery, Rostock University Medical Center, 18057 Rostock, Germany.
Anna SchildtCore Facility Multimodal Small Animal Imaging, Rostock University Medical Center, 18057 Rostock, Germany.
Markus JokschDepartment of Nuclear Medicine, Rostock University Medical Center, 18057 Rostock, Germany.
Bernd KrauseDepartment of Nuclear Medicine, Rostock University Medical Center, 18057 Rostock, Germany.
Robert JasterDivision of Gastroenterology, Department of Medicine II, Rostock University Medical Center, 18057 Rostock, Germany.ORCID 0000-0002-8220-4570
Rupert PalmeUnit of Experimental Endocrinology, Department of Biological Sciences and Pathobiology, University of Veterinary Medicine, 1210 Vienna, Austria.ORCID 0000-0001-9466-3662
Dietmar ZechnerRudolf-Zenker-Institute of Experimental Surgery, Rostock University Medical Center, 18057 Rostock, Germany.ORCID 0000-0002-2075-7540
Brigitte VollmarRudolf-Zenker-Institute of Experimental Surgery, Rostock University Medical Center, 18057 Rostock, Germany.
Simone KumstelRudolf-Zenker-Institute of Experimental Surgery, Rostock University Medical Center, 18057 Rostock, Germany.ORCID 0000-0001-6942-6294

Funding

Deutsche Forschungsgemeinschaft KU36301-1; TA 2072/1-1, ZE 712/1-2; VO450/15-2
6 · The paper itself

Abstract

Animal models are crucial to preclinical oncological research and drug development. Animal experiments must be performed in accordance with the 3R principles of replacement and reduction, if possible, and refinement where these procedures remain crucial. In addition, European Union legislations demand a continuous refinement approach, as well as pro- and retrospective severity assessment. In this study, an objective databased severity assessment was performed in murine models for pancreatic cancer induced by orthotopic, subcutaneous, or intravenous injection of Panc02 cells. Parameters such as body weight change, distress score, perianal temperature, mouse grimace scale, burrowing, nesting behavior, and the concentration of corticosterone in plasma and its metabolites in feces were monitored during tumor progression. The most important parameters were combined into a score and mapped against a reference data set by the Relative Severity Assessment procedure (RELSA) to obtain the maximum achieved severity for each animal (RELSA

Indexed as

animal modelspancreatic cancerrefinementseverity assessment

Identifiers

PMID39062067
PMCPMC11275077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.